We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer

This study has been withdrawn prior to enrollment.
(Study closed by Protocol Review Monitoring Committee because of lack of accrual)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01163929
First Posted: July 16, 2010
Last Update Posted: October 24, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Novartis
Information provided by (Responsible Party):
University of Kansas Medical Center ( University of Kansas )
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Study Completion Date: March 2012
  Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)